Biotech News

PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections

PolyPid (PYPD)PolyPidFDA / regulatory

Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX ₁₀₀ November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate targeting

Related news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control...

Recent company news

Stock data

Close
6.55 USD
Market cap
93.38M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States